Dihydroquercetin Improves Microvascularization and Microcirculation in the Brain Cortex of SHR Rats during the Development of Arterial Hypertension
- Authors: Plotnikov M.B.1, Aliev O.I.1, Sidekhmenova A.V.1, Shamanaev A.Y.1, Anishchenko A.M.1, Fomina T.I.1, Chernysheva G.A.1, Smol’yakova V.I.1, Arkhipov A.M.1
-
Affiliations:
- Laboratory of Circulation Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center
- Issue: Vol 163, No 1 (2017)
- Pages: 57-60
- Section: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/238644
- DOI: https://doi.org/10.1007/s10517-017-3737-7
- ID: 238644
Cite item
Abstract
The effects of dihydroquercetin (50 mg/kg intragastrically daily for 6 weeks) on the density of capillary network (mean number of capillaries per mm2), mean capillary diameter, structure of capillary network, capillary diameter distribution (<3, 3-5, 5-7, and 7-9 μ), and local cerebral blood flow (by laser Doppler) in the visual cortex were studied in SHR rats during the development of arterial hypertension (from the 6th to the 12th week of life). Normally, the systolic and diastolic BP progressively increased in SHR rats during this period. Dihydroquercetin did not affect the development of arterial hypertension. At the same time, the drug significantly increased the mean diameter of capillaries (by 11%), capillary network density (by 23%), and in the percentage of capillaries with a diameter of 3-9 μ (passable for erythrocytes; by 42%). Positive effects of dihydroquercetin on the structure of microcirculatory bed improved microcirculation: local cerebral blood flow in the visual cortex of SHR rats was significantly higher (by 36%) than in rats receiving no flavonoid and close to the value in Wistar-Kyoto rats. Dihydroquercetin improved microvascularization and microcirculation in the cerebral cortex of SHR rats during the formation of arterial hypertension.
About the authors
M. B. Plotnikov
Laboratory of Circulation Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center
Author for correspondence.
Email: mbp2001@mail.ru
Russian Federation, Tomsk
O. I. Aliev
Laboratory of Circulation Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center
Email: mbp2001@mail.ru
Russian Federation, Tomsk
A. V. Sidekhmenova
Laboratory of Circulation Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center
Email: mbp2001@mail.ru
Russian Federation, Tomsk
A. Yu. Shamanaev
Laboratory of Circulation Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center
Email: mbp2001@mail.ru
Russian Federation, Tomsk
A. M. Anishchenko
Laboratory of Circulation Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center
Email: mbp2001@mail.ru
Russian Federation, Tomsk
T. I. Fomina
Laboratory of Circulation Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center
Email: mbp2001@mail.ru
Russian Federation, Tomsk
G. A. Chernysheva
Laboratory of Circulation Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center
Email: mbp2001@mail.ru
Russian Federation, Tomsk
V. I. Smol’yakova
Laboratory of Circulation Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center
Email: mbp2001@mail.ru
Russian Federation, Tomsk
A. M. Arkhipov
Laboratory of Circulation Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Research Medical Center
Email: mbp2001@mail.ru
Russian Federation, Tomsk